Raymond James reiterates Outperform rating on Doximity stock at $75 target
PositiveFinancial Markets

Raymond James has reaffirmed its Outperform rating on Doximity's stock, setting a target price of $75. This endorsement reflects confidence in Doximity's business model and growth potential, which is significant for investors looking for promising opportunities in the healthcare technology sector.
— Curated by the World Pulse Now AI Editorial System